Our technology is originally based on quantum and statistical mechanics. At its heart is a theoretical framework to compute free energies of binding between a molecule and a target in water. This theory and the underlying algorithms rely on 8 years of academic research led by Maximilien Levesque, CEO of Aqemia, while he was a research group leader at École normale supérieure — PSL / CNRS, Cambridge and Oxford. The technology is described in more than 40 peer-reviewed articles in international journals and received several awards, for instance from the American Institute of Physics.
At Aqemia, we aspire to be at the forefront of AI and physics in drug discovery. Hence, we strive to push the boundaries with our technology and continue to publish.